Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-13

Clinical Trial Update: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating acalabrutinib after blood or marrow transplantation in mantle cell lymphoma; results posted in May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-05-13